- Roche launches an app ecosystem with the first two clinical decision support apps
- The apps query globally-renowned resources based on real-world data
- Patient-specific results lead to more personalised treatment decisions by oncology care teams
Basel, 18 September 2018 – Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the launch of the first two NAVIFY® clinical decision support apps: The NAVIFY Clinical Trial Match and NAVIFY Publication Search apps help oncology care teams access relevant clinical trial information and publications more effectively.
Finding the most relevant up-to-date clinical trials and relevant literature is a cumbersome and labour-intensive process. The two launched apps available on the NAVIFY Tumor Board facilitate this process:
NAVIFY Clinical Trial Match app identifies clinical trial options based on patient-specific attributes such as age, gender, biomarkers and various tumour information from 11 international registries (incl. ClinicalTrials.gov, German Clinical Trials Registry (DRKS) and European Clinical Trials Registry (EUCTR)).
NAVIFY Publication Search app mines publication sources globally (incl. PubMed, American Society of Clinical Oncology, American Association of Central Cancer Registries) for most recent clinically and therapeutically relevant literature. The content of both apps is provided by MolecularMatch, Inc., a clinical informatics company with expertise in precision oncology, immunotherapy and bioinformatics.
The launch of these first two apps is the start of the NAVIFY apps ecosystem. More apps from Roche, partners and third parties will follow to expand the clinical decision support functionalities.
“With our leading portfolio covering diagnostics, therapies and data, Roche is uniquely positioned to actively shape the digitalisation of healthcare. With innovative solutions such as the NAVIFY clinical decision support apps we move one step closer to offering more personalised care across the patient journey, from diagnosis to therapy decision, treatment and medical monitoring,” says Roche CEO Severin Schwan.
About NAVIFY decision support portfolio
The NAVIFY decision support portfolio helps multidisciplinary care teams navigate increasing complexity of medical information by transforming large amounts of data into actionable insights. The portfolio’s first commercially available product NAVIFY Tumor Board, a cloud-based software solution that fundamentally changes the way oncology care teams prepare for, conduct and document clinical treatment decisions, was launched in 2017. The portfolio is continuously evolving to include additional decision support solutions.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
– Nicolas Dunant (Head)
– Patrick Barth
– Ulrike Engels-Lange
– Simone Oeschger
– Anja von Treskow